Abstract
Systemic inflammation has been linked with the progression of cancer, and, in patients with urological cancers, the presence of a systemic inflammatory response is thought to be indicative of poor prognosis. C-reactive protein (CRP) is an acute-phase reactant, the levels of which can be objectively measured using standardized reliable assays, and a useful marker of systemic inflammation. CRP levels have been shown to predict survival in patients with urological cancers, including renal cell carcinoma, upper urinary tract and bladder cancers, and prostate cancer, and the incorporation of CRP into prognostic models for urological cancers improves the models' predictive accuracy. Furthermore, the kinetics of CRP release and the analysis of dynamic changes in CRP concentrations over time, could predict tumor aggressiveness and potential treatment efficacy. For instance, in long-term survivors of testicular cancer, CRP is associated with the risk of late complications, such as cardiovascular disease, and with the development of second non-germ-cell cancer. CRP could, therefore, be an important biomarker for urological cancers.
Key Points
-
The presence of a systemic inflammatory response, as evidenced by elevation of C-reactive protein (CRP) concentration, has been associated with poor prognosis in various malignancies including urological cancers
-
An increasing number of studies have shown that CRP is an important prognostic factor for renal cell carcinoma (RCC), upper urinary tract and bladder cancer, and prostate cancer
-
CRP has been incorporated into some prognostic algorithms for urological cancers (RCC and bladder cancer); this improves the predictive accuracy of the algorithms
-
The observation of dynamic changes in CRP concentration—CRP kinetics—contributes useful information for evaluating the risk of progression and mortality in RCC
-
In patients with testicular cancer, CRP is of prognostic importance in terms of predicting late complications, such as cardiovascular disease and second non-germ-cell cancer in long-term survivors who received systemic therapy
-
CRP meets the NIH criteria to be considered as a biomarker and could, therefore, be useful when assessing patients with urological cancers
Similar content being viewed by others
References
Cetin, K., Beebe-Dimmer, J. L., Fryzek, J. P., Markus, R. & Carducci, M. A. Recent time trends in the epidemiology of stage IV prostate cancer in the United States: analysis of data from the Surveillance, Epidemiology, and End Results Program. Urology 75, 1396–1404 (2010).
Raman, J. D., Messer, J., Sielatycki, J. A. & Hollenbeak, C. S. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005. BJU Int. 107, 1059–1064 (2011).
Sun, M. et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur. Urol. 59, 135–141 (2011).
Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89–95 (2001).
Roxburgh, C. S. & McMillan, D. C. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 6, 149–163 (2010).
Ferrero-Miliani, L., Nielsen, O. H., Andersen, P. S. & Girardin, S. E. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation. Clin. Exp. Immunol. 147, 227–235 (2007).
Tillet, W. S. & Francis, T. J. Serological reactions in peumonia with a non-protein somatic fraction of pneumococcus. J. Exp. Med. 521, 561–571 (1930).
Bottazzi, B., Doni, A., Garlanda, C. & Mantovani, A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu. Rev. Immunol. 28, 157–183 (2010).
Kushner, I., Jiang, S. L., Zhang, D., Lozanski, G. & Samols, D. Do post-transcriptional mechanisms participate in induction of C-reactive protein and serum amyloid A by IL-6 and IL-1? Ann. NY Acad. Sci. 762, 102–107 (1995).
Black, S., Kushner, I. & Samols, D. C-reactive Protein. J. Biol. Chem. 279, 48487–48490 (2004).
Agrawal, A., Samols, D. & Kushner, I. Transcription factor c-Rel enhances C-reactive protein expression by facilitating the binding of C/EBPbeta to the promoter. Mol. Immunol. 40, 373–380 (2003).
Jialal, I., Devaraj, S. & Venugopal, S. K. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 44, 6–11 (2004).
Kuta, A. E. & Baum, L. L. C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. J. Exp. Med. 164, 321–326 (1986).
Jabs, W. J. et al. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int. 68, 2103–2110 (2005).
Johnson, T. V. et al. Intratumor C-reactive protein as a biomarker of prognosis in localized renal cell carcinoma. J. Urol. 186, 1213–1217 (2011).
Janeway, C. A. Jr & Medzhitov, R. Innate immune recognition. Annu. Rev. Immunol. 20, 197–216 (2002).
Volanakis, J. E. Human C-reactive protein: expression, structure, and function. Mol. Immunol. 38, 189–197 (2001).
van Leeuwen, M. A. et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J. Rheumatol. 21, 425–429 (1994).
Nielen, M. M. et al. Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum. 50, 2423–2427 (2004).
Anderson, J. L., Carlquist, J. F., Muhlestein, J. B., Horne, B. D. & Elmer, S. P. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J. Am. Coll. Cardiol. 32, 35–41 (1998).
Danesh, J. et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350, 1387–1397 (2004).
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P. & Hennekens, C. H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336, 973–979 (1997).
Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883–899 (2010).
Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436–444 (2008).
Okamoto, M., Lee, C. & Oyasu, R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res. 57, 141–146 (1997).
Okamoto, M., Hattori, K. & Oyasu, R. Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int. J. Cancer 72, 149–154 (1997).
Miki, S. et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 250, 607–610 (1989).
Koo, A. S. et al. Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol. Immunother. 35, 97–105 (1992).
Tatokoro, M. et al. Phase-II trial of combination treatment of interferon-alpha, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci. 102, 137–143 (2011).
Rothwell, P. M. et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376, 1741–1750 (2010).
Dewys, W. D. et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69, 491–497 (1980).
Graf, W., Bergstrom, R., Pahlman, L. & Glimelius, B. Appraisal of a model for prediction of prognosis in advanced colorectal cancer. Eur. J. Cancer 30A, 453–457 (1994).
Maltoni, M. et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care. J. Clin. Oncol. 23, 6240–6248 (2005).
McMillan, D. C. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc. Nutr. Soc. 67, 257–262 (2008).
Proctor, M. J. et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur. J. Cancer http://dx.doi.org/10.1016/j.ejca.2011.03.028.
Saito, K. & Kihara, K. Role of C-reactive protein as a biomarker for renal cell carcinoma. Expert Rev. Anticancer Ther. 10, 1979–1989 (2010).
Iimura, Y. et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J. Urol. 181, 1004–1012 (2009).
Ito, K. et al. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int. J. Urol. 13, 1365–1370 (2006).
Jagdev, S. P. et al. Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein. Br. J. Cancer 103, 1649–1656 (2010).
Johnson, T. V. et al. Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma. J. Urol. 183, 480–485 (2010).
Karakiewicz, P. I. et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 110, 1241–1247 (2007).
Komai, Y., Saito, K., Sakai, K. & Morimoto, S. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int. 99, 77–80 (2007).
Lamb, G. W., McMillan, D. C., Ramsey, S. & Aitchison, M. The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br. J. Cancer 94, 781–784 (2006).
Masuda, H. et al. Prognostic factors for renal cell carcinoma: a multivariate analysis of 320 cases. Int. J. Urol. 4, 247–253 (1997).
Ramsey, S., Lamb, G. W., Aitchison, M. & McMillan, D. C. Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int. 101, 959–963 (2008).
Kattan, M. W. Judging new markers by their ability to improve predictive accuracy. J. Natl Cancer Inst. 95, 634–635 (2003).
Blay, J. Y., Negrier, S., Philip, T., Favrot, M. & Mercatello, A. Pretreatment serum CRP and response to interleukin 2. Br. J. Cancer 69, 200–201 (1994).
Miyake, H., Kurahashi, T., Takenaka, A., Inoue, T. A. & Fujisawa, M. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Urol. Oncol. 27, 598–603 (2009).
Coppin, C. et al. Immunotherapy for advanced renal cell cancer. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD001425. doi:10.1002/14651858.CD001425.pub2 (2005).
Vogl, U. M. et al. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br. J. Cancer 95, 691–698 (2006).
Bromwich, E., McMillan, D. C., Lamb, G. W., Vasey, P. A. & Aitchison, M. The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. Br. J. Cancer 91, 1236–1238 (2004).
Casamassima, A. et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J. Urol. 173, 52–55 (2005).
Naito, S. et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur. Urol. 57, 317–325 (2010).
Ramsey, S., Lamb, G. W., Aitchison, M., Graham, J. & McMillan, D. C. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 109, 205–212 (2007).
Atzpodien, J., Royston, P., Wandert, T. & Reitz, M. Metastatic renal carcinoma comprehensive prognostic system. Br. J. Cancer 88, 348–353 (2003).
Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P. & Mazumdar, M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20, 289–296 (2002).
Frank, I. et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol. 168, 2395–2400 (2002).
Novara, G., Martignoni, G., Artibani, W. & Ficarra, V. Grading systems in renal cell carcinoma. J. Urol. 177, 430–436 (2007).
Cindolo, L. et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 104, 1362–1371 (2005).
Johnson, T. V. et al. Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma. Urology 76, 766.e1–766.e5 (2010).
Tatokoro, M. et al. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J. Urol. 180, 515–519 (2008).
Shinohara, N. et al. Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma. Jpn J. Clin. Oncol. 39, 720–726 (2009).
Saito, K. et al. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur. Urol. 55, 1145–1153 (2009).
Takenawa, J. et al. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J. Natl Cancer Inst. 83, 1668–1672 (1991).
Saito, K. et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int. 100, 269–273 (2007).
Hilmy, M., Bartlett, J. M., Underwood, M. A. & McMillan, D. C. The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br. J. Cancer 92, 625–627 (2005).
Yoshida, S. et al. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int. 101, 978–981 (2008).
Gakis, G. et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int. http://dx.doi.org/10.1111/j.1464-410X.2011.10234.x.
Lehrer, S. et al. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int. 95, 961–962 (2005).
Van Hemelrijck, M. et al. Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation. Int. J. Cancer 129, 1485–1492 (2011).
Lee, S., Choe, J. W., Kim, H. K. & Sung, J. High-sensitivity C-reactive protein and cancer. J. Epidemiol. 21, 161–168 (2011).
McArdle, P. A., Qayyum, T. & McMillan, D. C. Systemic inflammatory response and survival in patients with localised prostate cancer: 10-year follow-up. Urol. Int. 84, 430–435 (2010).
McArdle, P. A. et al. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol. Int. 77, 127–129 (2006).
Nakashima, J. et al. Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases. Urol. Int. 80, 129–133 (2008).
Beer, T. M. et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer 112, 2377–2383 (2008).
Prins, R. C. et al. C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results. Urol. Oncol. http://dx.doi.org/10.1016/j.urolonc.2009.11.012.
Huddart, R. A. et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J. Clin. Oncol. 21, 1513–1523 (2003).
Meinardi, M. T. et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J. Clin. Oncol. 18, 1725–1732 (2000).
Fossa, S. D., Aass, N., Harvei, S. & Tretli, S. Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br. J. Cancer 90, 607–612 (2004).
Wethal, T. et al. Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer. J. Cancer Surviv. 1, 8–16 (2007).
Wethal, T. et al. C-reactive protein; a potential marker of second cancer and cardiovascular disease in testicular cancer survivors? Eur. J. Cancer 46, 3425–3433 (2010).
Orre, I. J. et al. Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue. Brain Behav. Immun. 23, 868–874 (2009).
Kushner, I. The phenomenon of the acute phase response. Ann. NY Acad. Sci. 389, 39–48 (1982).
Vanderschueren, S. et al. Extremely elevated C-reactive protein. Eur. J. Intern. Med. 17, 430–433 (2006).
Kushner, I., Rzewnicki, D. & Samols, D. What does minor elevation of C-reactive protein signify? Am. J. Med. 119, 166 e17–e28 (2006).
Rifai, N. & Ridker, P. M. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin. Chem. 47, 403–411 (2001).
Author information
Authors and Affiliations
Contributions
K. Saito researched and wrote the article. Both K. Saito and K. Kihara made equal contributions to discussion of content, and reviewing and editing the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Saito, K., Kihara, K. C-reactive protein as a biomarker for urological cancers. Nat Rev Urol 8, 659–666 (2011). https://doi.org/10.1038/nrurol.2011.145
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2011.145
- Springer Nature Limited
This article is cited by
-
The predictive value of perioperative circulating markers on surgical complications in patients undergoing robotic-assisted radical prostatectomy
World Journal of Surgical Oncology (2023)
-
C-reactive protein kinetics as a predictive marker for long-term outcome of immune checkpoint inhibitors in oesophagogastric cancer
BJC Reports (2023)
-
Impact of a novel immune and nutritional score on prognosis in patients with upper urinary tract urothelial carcinoma following radical nephroureterectomy
Journal of Cancer Research and Clinical Oncology (2023)
-
C-reactive protein/albumin ratio and Glasgow prognostic score are associated with prognosis and infiltration of Foxp3+ or CD3+ lymphocytes in colorectal liver metastasis
BMC Cancer (2022)
-
Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era
Targeted Oncology (2022)